ANDRO treatment, also reduced IL-1β and caspase-1 expression (Fig. 5C,D) (p ≤ 0.001), suggesting that ANDRO can modulate NASH progression by regulating the inflammasome. The gene discussed is CASP1; the disease is metabolic dysfunction-associated steatohepatitis.